Quvara Medical formed as Buckland Group Strengthens Advanced Manufacturing Portfolio
The new Quvara Medical site in Swindon will be a hub for quality validation manufacturing in healthcare products.
Buckland Group has completed its acquisition of Becton Dickinson’s (BD) Swindon manufacturing site, one of Europe’s leading high-precision, high-volume medical device production facilities.
The acquisition marks the creation of a new company: Quvara Medical. Quvara Medical joins the Buckland portfolio, along with Hi-Technology Group Ltd (Hi-Tech), which acquired Sabre Plastic Mouldings Ltd (Sabre) in a deal in March 2024, further enhancing the Group’s manufacturing and engineering offering. Quvara is a new contract manufacturing organisation positioned to deliver sustained value and scalable growth within the global healthcare supply chain.
Building on two decades of proven manufacturing excellence at the Swindon site, Quvara Medical enters the market with an established team, validated processes, and long-term supply agreements. The acquisition of the site by Buckland is part of BD’s ongoing network strategy to optimise its global supply chain, ensuring effective and efficient operations, while leveraging third-party partners and their expertise to deliver critical medical products to customers in Europe and around the world. Quvara will continue to manufacture BD’s existing product lines, while diversifying its portfolio to include pharmaceutical and medtech clients within the European market that are seeking reliable, compliant, and efficient manufacturing.
“This is a strategic investment in both capability and continuity,” said Neil Sibley, CEO of Quvara Medical & Hi-Tech Group. “Quvara combines the dependability of an established operation with the agility of a new, focused brand, giving investors confidence in our growth trajectory, and ensuring customers have peace of mind that there will be a smooth transition in the operation of Quvara, ensuring continuity of quality and capability, while enabling the facility to expand its services to additional pharmaceutical and medtech clients from day one.”
BD’s Swindon site represents a rare opportunity to acquire a fully validated, globally integrated operation at a time when the sector is consolidating rapidly. With increasing regulatory complexity and supply chain pressures, Buckland sees this acquisition as a strategic hedge against volatility and a platform for innovation.
Paul Bragg, Managing Director of Buckland Group, added: “Our model is to acquire strong operational platforms and align them with sector-specific growth strategies. Quvara Medical exemplifies this approach, leveraging a world-class facility to create long-term value across the healthcare manufacturing landscape.”
The Swindon acquisition expands Buckland Group’s manufacturing footprint to include operations in Waterlooville, Letchworth, and Košice (Slovakia), forming a resilient, multi-sector platform for future growth across healthcare, aerospace, and defence.